Copyright
©The Author(s) 2018.
World J Gastrointest Oncol. Dec 15, 2018; 10(12): 528-531
Published online Dec 15, 2018. doi: 10.4251/wjgo.v10.i12.528
Published online Dec 15, 2018. doi: 10.4251/wjgo.v10.i12.528
Figure 1 Spider plots of the response to 1st-line FOLFOXIRI plus bevacizumab in patients with RAS mutation (JACCRO CC-11).
A: Spider plots of tumor burden changes in patients with left-sided tumors (n = 44); B: Spider plots of tumor burden changes in patients with right-sided tumors (n = 17).
- Citation: Sunakawa Y, Satake H, Ichikawa W. Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors. World J Gastrointest Oncol 2018; 10(12): 528-531
- URL: https://www.wjgnet.com/1948-5204/full/v10/i12/528.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v10.i12.528